Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Prognostic Factors in Pancreatic Endocrine Neoplasms: An Analysis of 136 Cases With a Proposal for Low-Grade and Intermediate-Grade Groups PURPOSE: The HER-2/neu protein is a nonmutated tumor antigen ...
Prostate cancer begins as an androgen-dependent tumor that undergoes clinical regression in response to pharmacological or surgical strategies that reduce testosterone concentration. Despite this ...
Breast Tumor Section showing nonamplified HER-2/neu (<4 signals/nucleus). Cells are stained with DAPI. Probe is detected with flurorescein. There is perhaps nothing more disturbing to a woman than a ...
TUCSON, Ariz., Nov. 25, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC ...
The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...
Enhertu and Perjeta combination approved for first-line treatment of HER2-positive breast cancer, with companion diagnostics for patient identification. DESTINY-Breast09 trial showed improved ...
Trioar Inc. has synthesized antibody-drug conjugates comprising antibodies targeting HER2 (Neu, erbB2) covalently linked to cytotoxic drugs (particularly, MMAE and MMAF) through a linker reported to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results